Adam Tawney, MD
Interventional Cardiology · Royal Oak, MINPI 1962865147
Payments from drug & device makers
Across 178 payments — averaging $64.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Inari Medical, Inc.$3K
- Abbott$813
- Boston Scientific$580
- Merck$297
- Abiomed$278
- plus $3K from 32 others
What the payments were for
- Travel & lodging$4,22837%
- Food & beverage$6,58658%
- Education$5815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $4,156 |
| Inari Medical, Inc. | 13 | $2,598 |
| Abbott | 11 | $813 |
| Boston Scientific | 7 | $580 |
| Merck | 14 | $297 |
| Abiomed | 8 | $278 |
| Portola Pharmaceuticals, LLC | 2 | $228 |
| Amgen | 4 | $182 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $153 |
| Shockwave Medical, Inc | 3 | $152 |
| Alnylam Pharmaceuticals Inc. | 6 | $151 |
| Boehringer Ingelheim | 8 | $146 |
| Imperative Care, Inc | 1 | $144 |
| Kestra Medical Technology Services, Inc. | 6 | $142 |
| Pfizer | 6 | $141 |
| Johnson & Johnson | 2 | $125 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Esperion Therapeutics, Inc. | 7 | $117 |
| Philips North America LLC | 1 | $109 |
| Terumo Medical Corporation | 1 | $100 |
| Novo Nordisk | 3 | $69 |
| Recor Medical Inc | 3 | $68 |
| Chiesi USA, Inc. | 3 | $64 |
| Novartis | 3 | $56 |
| Edwards Lifesciences | 1 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Baxter Healthcare | 3 | $45 |
| AstraZeneca | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Bayer | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $22 |
| Heartflow, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $17 |
| Penumbra, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$2,772
- CT THROMBECTOMY SYSTEM KIT$2,059
- RESOLUTE ONYX$1,419
- Resolute$1,357
- ANDEXXA$228
- HeartMate 3 Left Ventricular Assist Device$197
- EnSite Precision Cardiac Mapping System$165
- Ultreon$161
- AVVIGO Guidance System$149
- SYMPHONY CATHETER$144
- Impella$139
- GENERAL - THERAPIES$137
- Repatha$129
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$126
- Diamondback Coronary$124
- AMVUTTRA$117
- SYNERGY$112
- (6575) Coronary Undivided$109
- XARELTO$103
- Perclose ProStyle$103
How this compares
$11,395 in reported general payments places this provider in the 55th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $181,387 |
| MounjaroTirzepatide | 31 | $34,269 |
| EntrestoSacubitril/Valsartan | 26 | $31,654 |
| JardianceEmpagliflozin | 17 | $14,282 |
| Repatha SureclickEvolocumab | 14 | $13,128 |
| BrilintaTicagrelor | 13 | $9,938 |
| Metoprolol Succinate | 187 | $2,711 |
| Rosuvastatin Calcium | 164 | $1,965 |
| Atorvastatin Calcium | 109 | $1,597 |
| Nifedipine ErNifedipine | 19 | $1,087 |
| Midodrine Hcl | 12 | $1,031 |
| Potassium Chloride | 16 | $775 |
| Losartan Potassium | 46 | $717 |
| Bumetanide | 26 | $644 |
| Ezetimibe | 30 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $141 | $181,387159 claims |
| NovartisEntresto | $56 | $31,65426 claims |
| Boehringer IngelheimJardiance | $146 | $14,28217 claims |
| AstraZenecaBrilinta | $41 | $9,93813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Royal Oak
- Ryan MadderRoyal Oak$239K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.